2023 – present Director and Tenured Chair Professor; AIDS Institute, Department of Microbiology, School of Clinical Medicine, State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR

2014 – 2023 Director and Tenured Full Professor; AIDS Institute, Department of Microbiology, School of Clinical Medicine, State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR

2007 – 2014 Director and Tenure-track Associate Professor, AIDS  Institute,  Department of Microbiology, State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR

2002 – 2007 Guest Professor and Ph.D. Advisor, State Key Laboratory of Virology of China, Modern Virology Research Center and AIDS Center, College of Life Sciences, Wuhan University, China

2002 – 2007 Staff Investigator and Assistant Professor, Aaron Diamond AIDS Research Center, The Rockefeller University, New York, USA

1999 – 2002 Research Scientist, Aaron Diamond AIDS Research Center, The Rockefeller University, New York, USA (Mentor: Professor David D. Ho)

1996 – 1999 Postdoctoral Fellow, Aaron Diamond AIDS Research Center, The Rockefeller University, New York, USA (Mentor: Professor David D. Ho)

1. Charles H. Revson/Norman and Rosita Winston Fellow 1998
2. US NIH F32 Fellow 1998-2002
3. Clinical Infectious Diseases Award for Outstanding Review 2010
4. JAIDS Outstanding Reviewer Award 2015
5. China New Development Award 2019 (Springer Nature)
6. Faculty Knowledge Exchange Award 2018-19 (HKUMed)
7. Knowledge Exchange Excellence Award 2019 (HKU)
8. Outstanding Researcher Award 2020-21 (HKU)
9. Outstanding Research Student Supervisor Award 2020-21 (HKU)
10. Gold Medal in Inventions Geneva Evaluation 2021
11. Faculty Outstanding Research Output Award 2021 (HKUMed)
12. Most Picked Award – 2021 Chinese Scientists with Cell Press (Cell Press)
13. Bronze Medal in Inventions Geneva Evaluation 2022
14. Faculty Outstanding Research Output Award 2022 (HKUMed)
15. Ranked by Clarivate Analytics as the top 1% worldwide by citations and one of HKU academics among Highly Cited Researchers 2022
16. Conferment of the title of Chair Professor by the president of The University of Hong Kong 2023
17. Faculty Outstanding Research Output Award 2023 (HKUMed)
18. Ranked by Clarivate Analytics as the top 1% worldwide by citations and one of HKU academics among Highly Cited Researchers 2023

1. Immunotherapy Advances, Founding Editorial Board Member, since 2020; Publisher: Oxford University Press, invited by British Society for Immunology
2. AIDS: Member of Editorial Board, since Jan 2017; Publisher: Lippincott Williams & Wilkins, USA
3. Journal of Acquired Immune Deficiency Syndromes (JAIDS); Member of Editorial Board, since Jan 2010; Publisher: Lippincott Williams & Wilkins, USA
4. Journal of Neuroimmune Pharmacology (JNIP); the peer-reviewed journal of the Society on NeuroImmune Pharmacology. Publisher: Springer
5. Journal of Leukocyte Biology, Guest editor, 2020
6. Current Opinion in HIV and AIDS, Invited guest editor for the November Issue 2020 on COVID-19, together with the invited Editorial
7. Journal of Medical Primatology, Member of Editorial Board, since 2008; Publisher: Blackwell-Wiley InterScience
8. PLoS ONE, Academic Editor and Member of Editorial Board since 2010; Publisher: Public Library of Science, USA
9. Journal of Antivirals and Antiretrovirals (Editor/Member of Editorial Board, since 2009); Publisher: OMICS Publishing Group
10. Faculty Member of F1000, F1000 Faculty comprises the world’s leading researchers across all of biology and medicine

1. 2014 Scientific Committee Member, 20th International AIDS Conference, Melbourne, by International AIDS Society
2. 2015 Scientific Advisory Board, Cent Gardes Conference: HIV Vaccines, France
3. 2016 Scientific Committee Member, Asia-pacific AIDS & Co-Infection Conference
4. 2017 Scientific Committee Member, Asia-pacific AIDS & Co-Infection Conference
5. 2018 Section chair at The HIV Research for Prevention (HIVR4P) international conference in Madrid
6. 2018 Scientific Committee Member, Asia-pacific AIDS & Co-Infection Conference
7. 2019 Invited Speaker, Cent Gardes Conference: HIV Vaccines, France
8. 2020 Invited plenary speaker at the Asia-Pacific AIDS & Co-Infections Conference 2020 in Thailand
9. 2020 Scientific Committee Member, Asia-pacific AIDS & Co-Infection Conference
10. 2020 Section Chair and Plenary Speaker, 5th International Conference & Expo on HIV & AIDS, the HIV-AIDS Summit 2020, Philadelphia, USA
11. 2022 Scientific Committee Member, Asia-pacific AIDS & Co-Infection Conference
12. IAS 2023: World’s largest scientific conference on HIV (Brisbane) by International AIDS Society, Abstract Selection Panel
13. IAS 2023, Invited Speaker, 2023 HIV Cure & Immunotherapy Forum; Section Chair for Advances in gene delivery and engineering of T and B cells: Implications for prevention, therapy and cure, Brisbane, Australia
14. AIDS 2024, basic research scientific committee member and reviewer, Munich, Germany

1. Hong Kong Health and Medical Fund (HMRF)
2. National Natural Science Foundation of China
3. Science, Technology and Innovation Commission of Shenzhen Municipality
4. American Foundation for AIDS Research (amFAR)
5. The Bill & Melinda Gates Foundation
6. Netherlands Organization for Scientific Research
7. British St Stephen’s AIDS Trust

1. Director, AIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong; July 2007 – present
2. Council member, Hong Kong Society for Immunology; Term: 2015 – present
3. Chairman, Hong Kong Society for Immunology; Term: 2018 – 2020
4. Member, Faculty BBMS Organizing Committee and Curriculum Committee; Term: 2015 – 2020
5. Member, Faculty High Degree Committee; Term: 2016 – 2019
6. Member, Advisory Council on AIDS, Department of Health, HKSAR; Term: 2008 – 2014
7. Board Director, Friends of Hope Education Fund, Hong Kong SAR; Term: 2008 – 2019; Initiated the AIDS orphan educational program, honorary board member
8. Board Director, AIDS Concern, Hong Kong SAR; Term: 2013 –
9. Board Director, Hong Kong AIDS Foundation, Hong Kong SAR; Term: 2019 – present; to promote HIV education and preventions programs
10. Member of Biology Panel, University Grants Committee, HKSAR; May 2024
11. Founding professor, Research Pandemic Alliance (RPA), Global; 2024

1. The American Society for Microbiology
2. The American Association of Immunologists
3. American Society on NeuroImmune Pharmacology
4. International AIDS Society

1. Director, AIDS Institute, Li Ka Shing Faculty of Medicine, The University of Hong Kong; July 2007 – present
2. Council member, Hong Kong Society for Immunology; Term: 2015 – present
3. Chairman, Hong Kong Society for Immunology; Term: 2018 – 2020
4. Member, Faculty BBMS Organizing Committee and Curriculum Committee; Term: 2015 – 2020
5. Member, Faculty High Degree Committee; Term: 2016 – 2019
6. Member, Advisory Council on AIDS, Department of Health, HKSAR; Term: 2008 – 2014
7. Board Director, Friends of Hope Education Fund, Hong Kong SAR; Term: 2008 – 2019; Initiated the AIDS orphan educational program, honorary board member
8. Board Director, AIDS Concern, Hong Kong SAR; Term: 2013 –
9. Board Director, Hong Kong AIDS Foundation, Hong Kong SAR; Term: 2019 – present; to promote HIV education and preventions programs
10. Member of Biology Panel, University Grants Committee, HKSAR; May 2024
11. Founding professor, Research Pandemic Alliance (RPA), Global; 2024

AIDS, JAIDS, Immunity, Science Translational Medicine, Lancet Infectious Disease, Lancet HIV, Journal of Virology, Journal of Clinical Investigation, Journal of Experimental Medicine, Emerging Microbes & Infections, Virology, Clinical Infectious Diseases, Journal of Infectious Diseases, Clinical Chemistry, Journal of Virological Methods, PLoS One, Journal of Immunology, Applied Microbiology and Biotechnology, Viruses, etc.

1998-1999 Fellowship award from the Charles H. Revson/Norman and Rosita Winston Foundation, The Rockefeller University. Role: Principal Investigator

1998-2002 Grant funded by National Institutes of Health (NIH/NIAID, 1F32AI 10256), Characterization of a CCR2-tropic recombinant simian immunodeficiency virus; Role: Principal Investigator

2000-2001 Grant funded by the American Foundation for AIDS Research (amFAR, 02663-27-RGM); Development of a Novel SHIV/Macaque Model for Microbicide Testing; Role: Principal Investigator

2005-2009 Grant from National Institutes of Health, USA; (NIH RO1 HL080211-01); A Novel Model for the Study of Lung Pathogenesis of SARS; Role: Principal Investigator

2007-2009 Grant from National Institutes of Health, USA; (NIH 5 R01 HL080211-03); US$2.4 million; A Novel Model for the Study of Lung Pathogenesis of SARS; Role: Principal Investigator

2007-2011 Grant from National Institutes of Health, USA; (NIH  3  R01 DA020419-02S1); Cannabinoid effects on HIV/AIDS; Role: Co-Principal Investigator

2008-2009 Grant BMGF 52117, Bill & Melinda Gates Foundation; Preventing HIV-1 infection using a novel vaccine immunogen; Role: Principal Investigator

2017-2021 Grant from Bill & Melinda Gates Foundation for the National Institutes of Health (AR170035), USA; Structure-Based Vaccine Design against HIV-1, Role: Co-Principal Investigator

2020 – 2022 Grant from Wellcome Trust (the Funder) for project entitled “A comprehensive study of immunopathogenesis of SARS-CoV-2 infection”, Role: Co-Principal Investigator

2020 – 2020    Phase I, Role: Co-Principal Investigator

2020 – 2022    Phase II, Role: Co-Principal Investigator

2020 – 2022 Grant from Australian MRFF 2020 COVID-19 Vaccine Candidate Grant Opportunity for project entitled “A safe, effective, and rapidly tuneable SARS-CoV-2 vaccine”, Role: Co-Investigator

2008-2009       Grant RGC-GRF 762208M, HKSAR;      Mucosal vaccine against HIV-1 infection; Role: Principal Investigator

2008-2009       Understanding the Ongoing HIV Epidemic in Yunnan China; Supported by China AIDS Initiative (Hong Kong Committee); Role: Principal Investigator

2009-2012       Grant RGC-GRF 762209M, HKSAR; Role of the PD-1/PD-L pathway in AIDS vaccine design; Role: Principal Investigator

2010-2012 Grant RFCID 09080772, HKSAR; Characterization of novel anti-HIV/TB natural product analogues; Role: Principal Investigator

2011-2013 AIDS Trust Fund (ATF) MSS 183 R, HKSAR; Establishment of a rapid, high-throughput, cost-effective HIV-1 drug resistance testing system; Role: Principal Investigator

2011-2013 Pneumoconiosis Compensation Fund Board (PCFB), HKSAR; A Novel Vaccine for Mesothelioma Immunotherapy and Prevention; Role: Principal Investigator

2011-2013 Grant RFCID 11101022, HKSAR, A Novel Vaccine for Tuberculosis Prevention; Role: Principal Investigator

2012-2014 Grant RGC-GRF 762811M, HKSAR; A Promising Mucosal Prime and Intramuscular Boost AIDS Vaccine Regimen; Role: Principal Investigator

2012-2015       Grant RGC-NSFC N_HKU 709/11, HKSAR; HIV prevention using gene-encoded neutralizing antibodies; HK$892,290; Role: Principal Investigator

2013-2015       Grant Information Technology Fund (ITF) GHX/013/11SZ, HK$682,642. Phenotypic Assay for HIV drug resistance; Role: Principal Investigator

2013-2016       Grant RGC-GRF 762712, HKSAR; Mechanism of soluble PD-1 based vaccine in amplifying antiviral CD8+ T-cell immunity; Role: Principal Investigator

2014-2016 Grant ITF ITS/194/13, HKSAR; A New Therapeutic Vaccine for HIV/AIDS; Role: Principal Investigator

2014-2017       Grant RGC-CRF HKU5/CRF/13G, HKSAR; Mechanism of potentiating HIV antigen-specific CD8+ T cells; Role: Project Coordinator

2014-2017       Grant ATF MSS 227R, HKSAR; The level of GFAP as a specific biomarker of neuroAIDS among Chinese patients; Role: Principal Investigator

2015-2016       Grant PCFB, HKSAR; Induction of Mesothelioma-Specific CD8+ T cells Response for Immunotherapy and Prevention; Role: Principal Investigator

2015-2019 Grant RGC-ANR A-HKU709/14, HKSAR; A novel DNA-based vaccination strategy to mimic Gag• specific responses found in HIV Elite Controllers; Role: Principal Investigator

2015-2017 Grant RGC-GRF 17103514, HKSAR; Role of a newly identified PD-1 isoform in modulating immune responses; Role: Principal Investigator

2015-2017 Grant HMRF 14130582, HKSAR; Role of Delta 42PD-1 in HIV Infection; Role: Principal Investigator

2016-2018 Grant RGC-GRF 17122915, HKSAR; Role of PD-1 Based Vaccine-Elicited CD8+ T Lymphocytes in Modulating MDSC-associated Immunosuppression; Role: Principal Investigator

2017-2018 Grant PCFB, HKSAR; Induction of Mesothelioma-Specific CD8+ T cells Response for Immunotherapy and Prevention; Role: Principal Investigator

2018-2019 Grant ITF ITS/170/17, HKSAR; A Novel Therapeutic AAV-vectored Bi-Specific Neutralizing Antibody against HIV/AIDS; Role: Principal Investigator

2018-2019 Grant ITF UIM/314, HKSAR; A novel PD1-based vaccine for HIV/AIDS Immunotherapy; Role: Principal Investigator

2018-2019 Grant PCFB, HKSAR; Enhancing immunotherapeutic efficacy of mesothelioma by overcoming MDSC-mediated immunosuppression; Role: Principal Investigator

2018-2021 Industry Contract Research, A Humanized anti-d42PD1 antibody against human inflammatory disease and cancer; Role: Principal Investigator

2019-2021 Grant RGC-GRF 17115818, HKSAR; Role of Δ42PD-1 in Human Dendritic Cells during HIV-1 Infection; Role: Principal Investigator

2019-2021 Grant HMRF 18170762, HKSAR; HIV-1 mucosal prevention and immunotherapy by engineered tandem bi-specific IgA; Role: Principal Investigator

2019-2023 Grant RGC-TRS T11-706/18-N, HKSAR; Potentiating Host Immunity for HIV-1 Functional Cure; Role: Project Co-ordinator

2020-2022 Grant RGC-GRF 17104919, HKSAR; Mechanism of a Δ42PD-1-specific humanized antibody huCH101 in treating HIV/AIDS; Role: Principal Investigator

2021-2023 Grant RGC-GRF 17121420, HKSAR; Combined BiIA-SG and

anti-TRABD2A antibody for HIV-1 Functional Cure; Role: Principal Investigator

2021-2024 Grant RGC-CRF C7156-20G, HKSAR; Mechanism of Immune Control against COVID-19; Role: Project Coordinator

2022-2025 Grant RGC-GRF 17117422, HKSAR; Mechanism of vaccine-induced mucosal immune responses against SARS-CoV-2 infection; Role: Principal Investigator

2023-2026 Grant RGC-GRF 1711923, HKSAR; Role of HIV-1-specific antibodies cloned from Δ42PD-1 positive memory B cells; Role: Principal Investigator

2024-2029  Grant ITC- RAISe+ RA1/23/072A, HKSAR; Research and development of the lead Δ42PD1 antibody drug as an immunotherapy against cancers and infections: Person-in-charge

2015-2018 Grant RGC-CRF C7038-14G, HKSAR; Investigation of  effects  and molecular mechanisms of FGFR2-positive cancer-associate fibroblasts on tumor microenvironment in esophageal squamous cell carcinoma; Role: Co-Principal Investigator

2017-2020 Grant from Sanming Project (AR160087); Study on AIDS Vaccine and Immunotherapy; Role: Project Leader

2019-2022 Grant RGC-CRF C4045-18W,  HKSAR;  Deciphering Enhancer Regulation of Tumor Immune Evasion to Develop New Combination Immunotherapies; Role: Co-Principal Investigator

2020-2022 HMRF Commissioned Research (COVID190123); “Clinical study of flu-based

and PD1-based vaccines for the SARS-CoV-2”; HK$10 million; Role: Co-Principal investigator

2020-2025 Grant RGC-TRS T12-703/19-R, HKSAR; Fighting Disease Recurrence and Promoting Tissue Repair after Liver Transplantation: Translating Basic Discoveries to Clinical Excellence; Role: Co-Principal Investigator

2020-2025 InnoHK “Centre for Virology, Vaccinology and Therapeutics”,  HKSAR; Role: Project Co-Principal Investigator

2021-2024     Grant RGC-CRF C1134-20G, HKSAR;  A novel vaccination strategy: using a microrobot platform for DNA vaccine delivery and antigen presentation; Role: Co-Principal Investigator

2022-2026 Grant RGC-TRS T11-709/21-N, HKSAR; Ecology, Molecular Virology and Pathogenesis of SARS-CoV-2: From Bedside to Bench and Back; Role: Co-Principal Investigator

2006-2010 Chinese 973 Research Program on HIV/AIDS; Role: Project 8 Leader

2008-2010 Grant from the China Ministry of Health; Novel AIDS mucosal vaccine (2008ZX10001-011); Role: Project Leader

2008-2010 Grant from the China Ministry of Health; (2008ZX10001-015); Microbicide against HIV; Role: Project Leader

2012-2015 Grant from the China Ministry of Health; Novel AIDS mucosal vaccine (China’s Major Project of the National Science & Technology 2012ZX10001-009); Role: Project 1 Leader

2013-2016 Grant from the China Ministry of Health; Novel Anti-HIV Antibody for Prevention (China’s Major Project of the National Science & Technology 2017ZX10201101-004); Role: Project 4 Leader

2020-2022 Grant from the Shenzhen Government at HKU SZH; PD1-based COVID-19 vaccine (ICCOV); JSGG20200225151410198; Role: Principal Investigator

2020-2022 Sub-grant from the Ministry of Science and Technology at HKU SZH; Mechanism of antibody-enhanced SARS-CoV-2 infection; 2020YFC0860600; Role: Co-Investigator

2022-2023 Grant from the Shenzhen Government at HKU SZH; Development portable Raman instrument for COVID disease detection; JSGG220220606141800002; Role: Co-Investigator

1. Chen Z, Telfer P, Reed P, Zhang L, Getti A, Ho DD and Marx Isolation and characterization of the first simian immunodeficiency virus from a feral sooty mangabey (Cercocebus atys) in West Africa. Journal of Medical Primatology. 24:108-115, 1995.
2. Chen Z, Telfer P, Gettie A, Reed P, Zhang L, Ho DD and Marx 1996. Genetic characterization of new West African simian immunodeficiency virus SIVsm: geographic clustering of household-derived SIV strains with human immunodeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop. Journal of Virology. 70:3617-3627, 1996.
3. Chen Z, Luckay A, Sodora DL, Telfer P, Reed P, Gettie A, Kanu JM, Sadek RF, Yee J, Ho DD, Zhang L and Marx PA. Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus  infected  sooty  mangabeys. Journal of Virology. 71:3953-3960, 1997.

4. Chen Z,  Zhou P,  Ho DD, Landau NR and Marx   Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. Journal of Virology. 71:2705-2714, 1997.
5. Georges-Courbot MC, Lu CY, Makuwa M, Telfer P, Onanga R, Dubreil, Chen Z, Smith SM, Georges A and Marx Natural Infection of a Household Pet Red-Capped Mangabey (Cercocebus torquatus torquatus) with a New Simian Immunodeficiency Virus. Journal of Virology. 72:600-8, 1998.
6. Chen Z, Gettie A, Ho DD and Marx Primary SIVsm isolates use the CCR5 co-receptor from sooty mangabeys naturally infected in West Africa: a comparison of coreceptor usage of primary SIVsm, HIV-2 and SIVmac. Virology. 246:113-124, 1998.
7. Marx PA and Chen Z. The function of simian chemokine receptors in the  replication of Seminars in Immunology. (Invited review article) 10:215-223, 1998.
8. Zhang L, He T, Huang Y, Chen Z, Guo Y, Wu S, Kunstman KJ, Brown RC, Phair JP, Neumann AU, Ho DD, Wolinsky Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. Journal of Virology. Nov; 72(11):9307-12, 1998. (IF: 5.402; Cited: 142.)
9. Palacios E, Digilio L, McClure HM, Chen Z, Marx PA, Goldsmith MA and Grant RM. Parallel evolution of CCR5-null phenotypes in humans and in a natural host of simian immunodeficiency virus. Current Biology. Jul 30-Aug 13;8(16):943-6,
10. Chen Z, Kwon D, Jin Z , Monard S, Telfer P, Jones MS, Aguilar R, Ho DD and Marx Natural infection of a homozygous deleted CCR5 red-capped mangabey with a CCR2b-tropic simian immunodeficiency virus. Journal of Experimental Medicine. Dec 7;188(11):2057-65, 1998.
11. Chen Z, Huang Y, Zhao X, Skulsky E, Lin D, Ip J, Gettie A and Ho DD. Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type 1 subtype C envelope after serial passages in pig-tailed macaques (Macaca nemestrina). Journal of Virology. 74:6501-10,
12. Chen Z, Zhao X, Huang Y, Huang YL, Gettie A, Ba L, Blanchard J and Ho DD. CD4+ Lymphocytopenia in Acute Infection of Asian Macaques by a Vaginally Transmissible Subtype-C, CCR5-Tropic Simian/Human Immunodeficiency Virus (SHIV). Journal of Acquired Immune Deficiency Syndromes. 30:133-145,
13. Lue J, Hsu M, Yang D, Marx P, Chen Z, and Cheng-Mayer C. Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1. Journal of Virology. Oct;76(20):10299-306,
14. Pohlmann S, Zhang J, Baribaud F, Chen Z, Leslie GJ, Lin G, Granelli-Piperno A, Doms RW, Rice CM, McKeating JA. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. Journal of Virology. Apr;77(7):4070-80,
15. Zhuang K, Gui X, Su B, Tien P, Chen Z, Zhang L. High prevalence of HIV  infection among women and their children in Henan Province, China. Journal of Acquired Immune Deficiency Syndromes. 33(5):649-50. 2003.
16. Su B, Liu L, Wang F, Gui X, Zhao M, Tien P, Zhang L and Chen Z*.  HIV-1 subtype B’ dictates the AIDS epidemic among paid blood donors in the Henan and Hubei provinces of China. AIDS. 21;17(17):2515-20. 2003.
17. Wu Z, Chen Z, Phillips DM. Human genital epithelial cells  capture  cell-free human immunodeficiency virus type 1 and transmit the virus to CD4+ Cells: implications for mechanisms of sexual transmission. The Journal of Infectious Diseases. 188(10):1473-82. 2003.
18. Kao RY, Tsui WH, Lee TS, Tanner JA, Watt RM, Huang JD, Hu L, Chen G, Chen Z, Zhang L, He T, Chan KH, Tse H, To AP, Ng LW, Wong BC, Tsoi HW, Yang D, Ho DD, Yuen KY. Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Chemistry & Biology. 2004 Sep;11(9):1293-9.
19. Zhang L, Chen Z, Cao Y, Yu J, Li G, Yu W, Yin N, Mei S, Li L, Balfe P, He T, Ba L, Zhang F, Lin HH, Yuen MF, Lai CL, Ho DD. Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in China. Journal of Virology. 78(24):13591-9. 2004. (Shared the first author)
20. Chen Z, Zhang L, Qin C, Ba L, Yi CE, Zhang F, Wei Q, He T, Yu W, Yu J, Gao H, Tu X, Gettie A, Farzan M, Yuen KY, Ho DD. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. Journal of Virology. 79(5):2678-88. 2005.
21. Fang Q, Yang L, Zhu W, Liu L, Wang H, Yu W, Xiao G, Tien P, Zhang L, Chen Z*. Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain. Virology. 10;335(2):242-51. 2005.
22. Yi CE, Ba L, Zhang L, Ho DD, Chen Z*. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. Journal of Virology. Sep;79(18):11638-46. 2005.
23. Woo PC, Lau SK, Tsoi HW, Chen Z, Wong BH, Zhang L, Chan JK, Wong LP, He W, Ma C, Chan KH, Ho DD, Yuen KY. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine. Oct 10;23(42):4959-4968. 2005.
24. Liu L, Su B, Zhuang K, Tien P, Chen Z, Zhang L. Genetic Characterization of Full-Length HIV Type 1 Genomes From 3 Infected Paid Blood Donors in Henan, China. Journal of Acquired Immune Deficiency Syndromes. 2005 Dec 1;40(4):501-503.
25. Chen Z, Zhu W, Fang Q, Zhuang K, Yu W, Wang H, Liu L, Tien P and Zhang L. Construction and characterization of a novel replication competent vaccinia Tiantan-based vector for vaccine development. Antiviral Therapy. 11(S2):171-172. 2006.

26. Chen Z, Fang Q, Zhuang K, Yu W, Zhu W, Wang H, Liu L, Tien P, Ho DD and Zhang L. A novel mucosal vaccinia vector for inducing high-level anti-viral immunity. Antiviral Therapy. 11(S2): 70-71. 2006.
27. Chen Z, Zhang Y, Lu L, Ba L, Yang L, Jia MH, Shi Y, Yan W, Chang G, Zhang L and Ho DD. A comprehensive molecular epidemiology study of HIV-1 subtypes in Yunnan Province of China. Antiviral Therapy. 11(S2):120-121. 2006.
28. Zhang L, Zhang F, Yu W, He T, Yu J, Yi CE, Ba L, Li W, Farzan M, Chen Z, Yuen KY, Ho D. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. Journal of Medical Virology. Jan;78(1):1-8. 2006.
29. Lin H-H, Gaschen BK, Collie M, EL-Fishaway M, Chen Z, Korber BT, Beatrice ST, Zhang L. Genetic Characterization of Human Immunodeficiency Virus Type I (HIV-1) Strains in an Immigrant Population Living in New York City. Journal of Acquired Immune Deficiency Syndromes. 2006 Apr 1;41(4):399-404..
30. Gardiner DF, Huang Y, Basu S, Leung L, Song Y, Chen Z, Ho DD. Multiple-site DNA vaccination enhances immune responses in mice. Vaccine. 2006 Jan 16;24(3):287-92. Epub 2005 Aug 8.
31. Pohlmann S, Munch J, Aziz S, Reeves JD, Otto C, Leslie GJ, Hofmann H, Puffer BA, Baribaud F, Marzi A, Gramberg T, Chen Z, Stolte N, Haaft PT, Heeney JL, Stahl-Hennig C, Matz-Rensing K, Schneider T, Doms RW, Kirchhoff F. A simian immunodeficiency virus V3 loop mutant that does not efficiently use CCR5 or common alternative coreceptors is moderately attenuated in vivo. Virology. 2007 Apr 10;360(2):275-85.
32. Zhang Y, Lu L, Ba L, Liu L, Yang L, Jia M, Wang H, Fang Q, Shi Y, Yan W, Chang G, Zhang L, Ho DD, Chen Z*. Dominance of HIV-1 subtype CRF01_AE in sexually acquired cases leads to a new epidemic in Yunnan province of China. PLoS Medicine. 2006 Nov;3(11):e443.
33. Liu L, Fang Q, Deng F, Wang H, Yi C, Ba L, Yu W, Lin RD, Li T, Hu ZH, Ho DD, Zhang L, Chen Z*. Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus. Journal of Virology. 2007. May;81(9):4694-700.
34. Li T, Xie J, He Y, Fan H, Baril L, Qiu Z, Han Y, Xu W, Zhang W, You H, Zuo Y, Fang Q, Yu J, Chen Z, Zhang L. Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus. PLoS ONE. 2006 Dec 20;1:e24.
35. Ma D, Yu S, Li B, Chen L, Chen R, Yu K, Zhang L, Chen Z, Zhong D, Gong Z, Wang R, Jiang H, Pei G. Synthesis and Biological Evaluation of 1,3,3,4-Tetrasubstituted Pyrrolidine CCR5 Receptor Antagonists. Discovery of a Potent and Orally Bioavailable Anti-HIV Agent. ChemMedChem. 2007 Feb 12;2(2):187-193.
36. Zhu W, Fang Q, Liu L, Wang H, Zhou J, Yu W, Tien P, Zhang L, Chen Z*. The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes. Journal of Virological Methods. 2007 Sep;144(1-2):17-26.
37. Ba L, Yi CE, Zhang L, Ho DD, Chen Z*. Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus. Applied Microbiology and Biotechnology. 2007 Oct;76(5):1131-6.
38. Ma T, Gao Q, Chen Z, Wang L, Liu G. Chemical resolution of ()-calanolide A, ()-cordatolide A and their 11-demethyl analogues. Bioorganic & Medicinal Chemistry Letters. 2008 Feb 1;18(3):1079-83.
39. Ma T, Liu L, Xue H, Li L, Han C, Wang L, Chen Z, Liu G. Chemical library and structure-activity relationships of 11-demethyl-12-oxo calanolide A analogues as anti-HIV-1 agents. Journal of Medicinal Chemistry. 2008 Mar 13;51(5):1432-46.
40. Chen Z, Huang Y, Zhao X, Ba L, Zhang W and Ho DD. Design, Construction, and Characterization of a Multigenic Modified Vaccinia Ankara Candidate Vaccine against Human Immunodeficiency Virus Type 1 Subtype C/B’. Journal of Acquired Immune Deficiency Syndromes. 2008 Apr 1;47(4):412-21.
41. Huang Y, Chen Z, Zhang W, Song Y, Zhao X, Gardiner DF and Ho DD. Design, Construction, and Characterization of a Dual-Promoter Multigenic DNA Vaccine Directed against an HIV-1 Subtype C/B’ Recombinant. Journal of Acquired Immune Deficiency Syndromes. 2008 Apr 1;47(4):403-11.
42. Huang Y, Chen A, Li X, Chen Z, Zhang W, Song Y, Gurner D, Gardiner D, Basu S, Ho DD, Tsuji M. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide. Vaccine. 2008 Mar 28;26(15):1807-16.
43. Chen YX, Liu L, Wei Q, Zhu H, Jiang H, Tu XM, Qin C and Chen Z*. Rhesus angiotensin converting enzyme 2 supports entry of severe acute respiratory syndrome coronavirus in Chinese macaques. Virology. 2008 Nov 10;381(1):89-97.
44. Lu L, Jia M, Ma Y, Yang L, Chen Z, Ho DD, Jiang Y, Zhang L. The Changing Face of HIV in China. Nature. Oct 2. 455:609-11, 2008.
45. Luo M, Liu H, Zhuang K, Liu L, Su B, Yang R, Tien P, Zhang L, Gui X and Chen Z*. Prevalence of drug resistant HIV-1 in rural areas of Hubei province in the People’s Republic of China. Journal of Acquired Immune Deficiency Syndromes. Jan 1; 50(1): 1-8. 2009.
46. Bian C, Zhang X, Cai X, Zhang L, Chen Z, Zha Y, Xu Y, Xu K, Lu W, Yan L, Yuan J, Feng J, Hao P, Wang Q, Zhao G, Liu G, Zhu X, Shen H, Zheng B, Shen B, Sun B. Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody. Virology. 2009 Jan 5;383(1):39-46.
47. Huang XX, Lu B, Fang Q, Yu W, Liu L, Zhuang K, Shen TT, Wang HB, Tian P, Zhang L, and Chen Z*. A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS ONE. 2009;4(1):e4180.
48. Cheng S, LI J, Lin B, Lee D, Liu L, Chen Z, Lau A. HIV-1 trans-activator protein induction of suppressor of cytokine signaling-2 contributes to dysregulation of IFN signaling. Blood. 2009 May 21;113(21):5192-201.
49. Xu L, Zhang YF, Liu Y, Chen Z, Deng H, Ma Z, Wang H, Hu Z, and Fei Deng F. Angiotensin-converting enzyme 2 (ACE2) from raccoon dog can serve as an efficient receptor for the spike protein of severe acute respiratory syndrome coronavirus. Journal of General Virology. 2009 Nov. 90:2695-2703.
50. Chen Z, Sun C, Du Y, Chen L and Zhang L. Effective control of a pathogenic SIVmac239 challenge by a novel heterologous mucosal prime and intramuscular boost vaccine strategy. Retrovirology. 2009, 6 (S3):419.
51. Vasan S, Schlesinger SJ, Huang Y, Hurley A, Lombardo A, Chen Z, Than S, Adesanya P, Bunce C, Boaz M, Boyle R, Sayeed E, Clark L, Dugin D, Schmidt C, Song Y, Seamons L, Dally L, Ho M, Smith C, Markowitz M, Cox J, Gill DK, Gilmour J, Keefer MC, Fast P, Ho DD. Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-based Clade C/B’ HIV-1 Candidate Vaccine. PLoS ONE. 2010 Jan; 5(1):e8617.
52. Vasan S, Schlesinger SJ, Chen Z, Hurley A, Lombardo A, Than S, Adesanya P, Bunce C, Boaz M, Boyle R, Sayeed E, Clark L, Dugin D, Boente-Carrera M, Schmidt C, Fang Q, LeiBa, Huang Y, Zaharatos GJ, Gardiner DF, Caskey M, Seamons L, Ho M, Dally L, Smith C, Cox J, Gill D, Gilmour J, Keefer MC, Fast P, Ho DD. Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-based Clade C/B’ HIV-1 Candidate Vaccine. PLoS ONE. 2010 Jan; 5(1):e8816.
53. Xue H, Lu XF, Zheng PR, Liu L, Han CY, Hu JP, Liu ZJ, Ma T, Li Y, Wang L, Chen Z* and Liu G*. Highly suppressing wild-type HIV-1 and Y181C Mutant HIV-1 Strains by 10-Chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile. Journal of Medicinal Chemistry. 53(3), pp1397-1401. 2010.
54. Yu W, Fang Q, Zhu W, Wang H, Tien P, Zhang L, and Chen Z*. One time intranasal vaccination with a modified vaccinia Tiantan strain MVTT (ZCI) protects animals against pathogenic viral challenge. Vaccine. 2010 Feb 25;28(9):2088-96.
55. Tang X and Chen Z*. The development of an AIDS mucosal vaccine. Viruses. 2010, 2(1), 283-297. (Invited review article)
56. Wang H, Zhuang K, Liu L, Tang Z, Tang J, Tien P, Zhang L, and Chen Z*. Acute infection of Chinese macaques by a CCR5-tropic SHIV carrying a primary HIV-1 subtype B’ envelope. Journal of Acquired Immune Deficiency Syndromes. Mar 1:53(3):285-291. 2010.
57. Liu H, Yu W, Zhu W, Wang H, and Chen Z*. The route of inoculation determines the tissue tropism of modified vaccinia Tiantan expressing the spike glycoprotein of SARS-CoV in mice. Journal of Medical Virology. 2010 May;82(5):727-34.
58. Lu XF and Chen Z*. The development of anti-HIV drugs. ACTA Pharmaceutica Sinica. 2010. 45(2): 165-176. (Invited review article)
59. Chen JH-K, Wong K-H, Chen Z, Chan K, Lam H-Y, et al. Increased Genetic Diversity of HIV-1 Circulating in Hong Kong. PLoS ONE. 2010. 5(8): e12198.
60. Jiang B, Qin L, Du Y, Peng N, Chen L, Chen Z, Chen X. Transgenic Plasmodium that expresses HIV-1 Gag elicits immunity and protects mice against vaccinia virus-gag and malarial parasites. Vaccine. 2010 Nov 23;28(50):7915-22.
61. Chen JH, Wong KH, Chan KC, To SW, Chen Z, Yam WC. Phylodynamics of HIV-1 subtype B among the men-having-sex-with-men (MSM) population in Hong Kong. PLoS One. 2011;6(9):e25286. Epub 2011 Sep 22.
62. Liu L, Wei Q, Alvarez X, Wang H, Du Y, Zhu H, Jiang H, Zhou J, Lam P, Zhang L, Lackner A, Qin C, Chen Z*. Epithelial Cells Lining Salivary Gland Ducts Are Early Target Cells of Severe Acute Respiratory Syndrome Coronavirus Infection in the Upper Respiratory Tract of Rhesus Macaques. Journal of Virology. 2011. 85(8b):4025-4030.
63. Lu B, Yu W, Huang XX, Wang H, Liu L, and Chen Z*. Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replication-competent smallpox vaccine, vaccinia Tiantan strain. Journal of Biomedicine and Biotechnology. 2011;2011:970424.
64. Lu X, Liu L, Zhang X, Lau TC, Tsui SK, Kang Y, Zheng P, Zheng B, Liu G, Chen Z*. F18, a novel small molecule NNRTI, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis. Antimicrob Agents Chemother. 2012 Jan;56(1):341-51.
65. Zhang Q, Zhang X, Wu H, Seto D, Zhang H-J, Chen Z, Wan CS, Zheng BJ. Parental LTRs Are Important in a Construct of a Stable and Efficient Replication-Competent Infectious Molecular Clone of HIV-1 CRF08_BC. PLoS ONE. 2012 Feb; 7(2): e31233. doi:10.1371/journal.pone.0031233
66. Liu Z, Li L, Chen Z, Xu M, Zhang T, Jiao Y, Sheng B, Chen D and Wu Prevalence  of GB virus type C viraemia in MSM with or without HIV-1 infection in Beijing, China. Epidemiology & Infection. 2012 Dec;140(12):2199-209.
67. Yao X, Wang H, Yan P, Lu Y, Lin H, Chen L, Ng J, Lau E, Li L, Wu J, Chen Z*. Rising epidemic of HIV-1 infections among general populations in Fujian, China. Journal of Acquired Immune Deficiency Syndromes. 2012 Jul; 60(3): 328-35.
68. Zhou F, Wang G, Buchy P, Cai Z, Chen H, Chen Z, Cheng G, Wan XF, Deubel V, Zhou P. A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses. Journal of Virology. 2012 Jun; 86(12): 6970-8.
69. Qiu M, Wang Q, Chu Y, Yuan Z, Song HY, Chen Z*, and Wu Z* Lignosulfonic acid shows potent antiretroviral activity – potential as a microbicide candidate for the prevention of HIV-1 sexual transmission. PLoS One. 2012 Apr; 7(4): e35906. doi:10.1371/journal.pone.0035906
70. Kang Y, Wu Z, Lau TC, Lu X, Liu L, Cheung AK, Tan Z, Ng J, Liang J, Wang H, Li S, Zheng B, Li B, Chen L, Chen Z*. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant. The Journal of Biological Chemistry. 2012 May; 287(20):16499-509.
71. Qiu M, Chen Y, Song S, Song H, Chu Y, Yuan Z, Cheng L, Zheng D, Chen Z, Wu Z. Poly (4-styrenesulfonic acid-co-maleic acid) is an entry inhibitor against both HIV-1 and HSV infections – potential as a dual functional microbicide. Antiviral Research. 2012 November; 96(2):138-47.
72. Kang Y, Guo J and Chen Z*. Closing the door to human immunodeficiency virus. Protein & Cell. 2013 Feb; 4(2):86-102 (Invited Review Article)
73. Zhou J, Cheung AKL, Tan Z, Wang H, Kang Y, Du Y, Lu X, Liu L, Yuen KY and Chen Z*. PD1-based DNA vaccine amplifies HIV-1 CD8+ T cells in mice. Journal of Clinical Investigation. 2013 Jul; 123(6):2629–2642.
74. Sun C, Chen Z*, Tang X, Zhang Y, Feng L, Du Y, Xiao L, Liu L, Chen L, Zhang L. Mucosal Prime with a Replicating Vaccinia-based Vaccine Elicits Protective Immunity against SIV Challenge in Rhesus Monkeys. Journal of Virology. 2013 May; 87(10):5669-77. (Shared first author and corresponding author)
75. Zhou J, Cheung AKL, Liu H, Tan Z, Tang X, Kang Y, Du Y, Wang H, Liu L, and Chen Z*. Potentiating functional antigen-specific CD8+ T cell immunity  by  a novel PD1 isoform-based fusion DNA vaccine. Molecular Therapy. 2013 Jul; 21(7):1445-55.
76. Peng Q, Wang H, Wang H, Li X, Lu X, Zhou B, and Chen Z*. Imbalances of gut-homing CD4+ T cell subsets in HIV-1 infected Chinese patients. Journal of Acquired Immune Deficiency Syndromes. 2013 Sep; 64(1):25-31.
77. To SW, Chen JH, Wong KH, Chan KC, Chen Z, Yam WC. Determination of the High Prevalence of Dual/Mixed- or X4-Tropism Among HIV Type 1 CRF01_AE in Hong Kong by Genotyping and Phenotyping Methods. AIDS Research and Human Retroviruses. 2013 August; 29(8):1123-8.
78. Zhang Y, Xu J, San Q, Shao Y, Chen Z and Zhang MY. The potential of the human immune system to develop broadly neutralizing HIV-1 antibodies: implications for vaccine development. AIDS. 2013 Oct; 27(16):2529-39.
79. Xiao H, Liu L, Zhu Q, Tan Z, Yu W, Tang X, Zhan D, Du Y, Wang H, Liu D, Li Z, Yuen KY, Ho DD, Gao GF, Chen Z*. A replicating modified vaccinia tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in mice. PLoS One. 2013 Dec 17;8(12):e83274.
80. Liang JG, JP Chen, Tan ZW, Peng J, Zheng X, Nishiura KJ, Ng J, Wang ZY, Wang DM, Chen Z* and Liu L*. Extracts of medicinal herb Sanguisorba officinalis inhibit the entry of human immunodeficiency virus type one. Journal of Food and Drug Analysis. 2013 Dec; 21(4):S52-S58.
81. Chen Z* and Zhou J. Strengthening the role of dendritic cells in AIDS vaccine development. Journal of Antivirals & Antiretrovirals. 2013 Aug. 5: xxiii-xxiv. (Invited Editorial Article).
82. Tan Z, Zhou J, Cheung AK, Yu Z, Cheung KW, Liang J, Wang H, Lee BK, Man K, Liu L, Yuen KY, Chen Z*. Vaccine-elicited CD8+ T cells cure mesothelioma by overcoming tumor-induced immunosuppressive environment. Cancer Research. 2014 Aug; 74:6010-21.
83. Wu H, Zhang XM, Zhang HJ, Zhang, Q, Chen Z, Huang JD, Lee SS, Zheng BJ. In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors. AIDS Research and Human Retroviruses. 2015;31(2):260-70.
84. Guo J, Zuo T, Cheng L, Wu X, Tang J, Sun C, Feng L, Chen L, Zhang L, Chen Z*. Simian immunodeficiency virus infection evades vaccine-elicited antibody responses to V2 region. Journal of Acquired Immune Deficiency Syndromes. 2015 Apr; 68(5):502-10.
85. Liang J, Liu L, Cheung M, Lee MP, Wang H, Li CH, Chan CC, Nishiura K, Tang X, Tan Z, Peng J, Cheung KW, Yam WC, Chen Z*. Community-Based HIV-1 Early Diagnosis and Risk Behavior Analysis of Men Having Sex with Men in Hong Kong. PLoS One. 2015 Apr 27;10(4):e0125715.
86. Zhang XM, Wu H, Zhang Q, Lau TC, Chu H, Chen Z, Jin DY, Zheng BJ. A novel mutation, D404N, in the connection subdomain of reverse transcriptase of HIV-1 CRF08_BC subtype confers cross-resistance to NNRTIs. Journal of Antimicrobial Chemotherapy. 2015 May;70(5):1381-90.
87. Zhang Y, Li SK, Yang YK, Liu M, Lee N, Tang X, Wang H, Liu L, Chen Z, Zhang C, Wang J, Kwok-Wing Tsui Whole genome methylation array reveals the down-regulation of IGFBP6 and SATB2 by HIV-1. Scientific Reports. 2015 Jun 3;5:10806..
88. Cheng L, Tang X, Liu L, Peng J, Nishiura K, Cheung AK, Guo J, Wu X, Tang HY, An M, Zhou J, Cheung KW, Wang H, Guan X, Wu Z, Chen Z*. Monoclonal antibodies specific to human Δ42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis. MAbs 2015 July; 7(3): 620-9.
89. Cong Z, Xue J, Xiong J, Yao N, Wang W, Jiang H, Chen T, Chen Z, Wei Q, Qin C. Correlation of central memory CD4+ T-Cell decrease in the peripheral blood with disease progression in SIVmac251-infected Chinese rhesus macaques. Journal of Medical Primatology 2015 Aug;44(4):175-82. doi: 10.1111/jmp.12171.
90. Zhe Y, Tan Z, Lee BK, Tang J, Wu X, Cheung KW, Lo NTL, Man K, Liu L, Chen Z*. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells. Oncotarget. 2015 Oct; 6(32): 32426-38.
91. Lai KK, Cheung NN, Yang F, Dai J, Liu L, Chen Z, Sze KH, Chen H, Yuen KY, Kao RY. Identification of Novel Fusion Inhibitors of Influenza A Virus by Chemical Genetics. Journal of Virology. 2016;90(5):2690-701. doi:10.1128/JVI.02326-15
92. Cheung KW, Peng Q, He L, Cai K, Jiang Q, Zhou B, To SW, Yam WC, Liu L, Chen Z*, Wang H. Rapid and Simultaneous Detection of Major Drug Resistance Mutations in Reverse Transcriptase Gene for HIV-1 CRF01_AE, CRF07_BC and Subtype B in China Using Sequenom MassARRAY® System. PLoS One. 2016 Apr; 11(4):e0153641.
93. Tang J, Yam WC, Chen Z. Mycobacterium tuberculosis infection and vaccine development. Tuberculosis (Edinb). 2016 May;98:30-41.
94. Liu L, Wei Q, Nishiura K, Peng J, Wang H, Midkiff C, Alvarez X, Qin C, Lackner A and Chen Z*. Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques. Mucosal Immunology. 2016 Jul; 9(4):1089-101.
95. Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, Barre-Sinoussi F; International AIDS Society Towards a Cure Working Group, Alter G, Auerbach J, Autran B, Barouch DH, Behrens G, Cavazzana M, Chen Z, Cohen É, Corbelli GM, Eholié S, Eyal N, Fidler S, Garcia L, Grossman C, Henderson G, Henrich TJ, Jefferys R, Kiem HP, McCune J, Moodley K, Newman PA, Nijhuis M, Nsubuga MS, Ott M, Palmer S, Richman D, Saez-Cirion A, Sharp M, Siliciano J, Silvestri G, Singh J, Spire B, Taylor J, Tolstrup M, Valente S, van Lunzen J, Walensky R, Wilson I, Zack J. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine. 2016 Aug;22(8):839-50.
96. Ren H, Wang G, Wang S, Chen H, ChenZ, Hu H, Cheng G and Zhou P. Cross-protection of newly emerging HPAI H5 viruses by neutralizing human monoclonal antibodies: A viable alternative to oseltamivir. MAbs. 2016 Aug-Sep; 8(6): 1156–1166.
97. Li MD, Hser YI, Chen Z, Chang L. Promoting Global Health – Prevention and Treatment of Substance Abuse and HIV in Asia. Journal of Neuroimmune Pharmacology. 2016 Sep;11(3):379-82.
98. Wu X, Liu L, Cheung KW, Wang H, Lu X, Cheung AK, Liu W, Huang X, Li Y, Chen ZW, Chen SM, Zhang T, Wu H, Chen Z*..Brain Invasion by CD4(+) T Cells Infected with a Transmitted/Founder HIV-1BJZS7 During Acute Stage in Humanized Mice. Journal of Neuroimmune Pharmacology. 2016 Sep; 11(3):572-83.
99. Wei Q, Liu L, Cong Z, Wu X, Wang H, Qin C, Molina P, Chen Z*. Chronic Δ(9)-Tetrahydrocannabinol Administration Reduces IgE(+)B Cells but Unlikely Enhances Pathogenic SIVmac251 Infection in Male Rhesus Macaques of Chinese Origin. Journal of Neuroimmune Pharmacology. 2016 Sep;11(3):584-591.
100. Lau SK, Woo PC, Li KS, Zhang HJ, Fan RY, Zhang AJ, Chan BC, Lam CS, Yip CC, Yuen MC, Chan KH, Chen ZW, Yuen KY. Identification of Novel Rosavirus Species That Infects Diverse Rodent Species and Causes Multisystemic Dissemination in Mouse Model. PLoS Pathogens. 2016 Oct 13;12(10):e1005911.
101. Liu L, Wang W, Matz J, Ye C, Bracq L, Delon J, Kimata JT, Chen Z, Benichou S, Zhou P. The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1. Journal of Virology. 2016 Nov 14;90(23):10642-10659.
102. Cheung A.K., Huang Y., Kwok H.Y., Chen M., Chen Z*. Latent human cytomegalovirus enhances HIV-1 infection in CD34+ progenitor cells. Blood Advances. 2017 Jan; 1(5):306-318.
103. Liu M, Zhou J, Chen Z, Cheng AS. Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy. The Journal of Pathology. 2017 Jan;241(1):10-24.
104. Jiang W, Wang S, Chen H, Ren H, Huang X, Wang G, Chen Z, Chen L, Chen Z, Zhou P. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses. Journal of Virology. 2017 Apr 13;91(9). pii: e02052-16.
105. To KKW, Chan WM, Li KSM, Lam CSF, Chen Z, Tse H, Lau SKP, Woo PCY, Yuen KY. High prevalence of four novel astrovirus genotype species identified from rodents in China. Journal of General Virology. 2017 May;98(5):1004-1015.
106. Hser YI, Li MD, Grella C, Brecht L, Chen Z, Chang SL, Chang L, Normand J, Tai B. The 2017 CALDAR Summer Institute and International Conference Promoting Global Health-Precision Research in Substance Abuse, HIV, and Care. J Neuroimmune 2017    Jun;      12(Suppl          2):79-80.          doi: 10.1007/s11481-017-9750-9.PMID: 28497234
107. Cheung AK, Kwok HY, Huang Y, Chen M, Mo Y, Wu X, Lam KS, Kong HK, Lau TCK, Zhou J, Li J, Cheng L, Lee BK, Peng Q, Lu X, An M, Wang H, Shang H, Zhou B, Wu H, Xu A, Yuen KY, Chen Z*. Gut-homing Δ42PD1+Vδ2 T cells promote innate mucosal damage via TLR4 during acute HIV type 1 infection. Nature Microbiology. 2017 Oct;2(10):1389-1402.
108. Tang X, Guo J, Cheng L, Sun C, Liu L, Zuo T, Wang H, Chen L, Zhang L, Chen Z*. Single N277A substitution in C2 of simian immunodeficiency virus envelope influences vaccine-elicited CD4i neutralizing and anti-V2 antibody responses. Vaccine. 2017 May 2;35(19):2582-2591.
109. Wu X, Guo J, Niu M, An M, Liu L, Wang H, Jin X, Zhang Q, Lam KS, Wu T, Wang H, Wang Q, Du Y, Li J, Cheng L, Tang HY, Shang H, Zhang L, Zhou P, Chen Z*. Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice. Journal of Clinical Investigation. 2018 Apr 23. pii: 96764.
110. Zhou J, Liu M, Sun H, Feng Y, Xu L, Chan AWH, Tong JH, Wong J, Chong CCN, Lai PBS, Wang HK, Tsang SW, Goodwin T, Liu R, Huang L, Chen Z, Sung JJ, Chow KL, To KF, Cheng AS Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut. 2018 May;67(5):931-944.
111. Liu W, Wong YC, Chen SMY, Tang J, Wang H, Cheung AKL, Chen Z*. DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses. Vaccine. 2018 Jul 25;36(31):4621-4632.
112. Wang S, Ren H, Jiang W, Chen H, Hu H, Chen Z, Zhou P. Divergent Requirement of Fc-Fcγ Receptor Interactions for In Vivo Protection against Influenza Viruses by Two Pan-H5 Hemagglutinin Antibodies. Journal of Virology 2017 May 12;91(11). pii: e02065-16.
113. Gao N, Wang W, Wang C, Gu T, Guo R, Yu B, Kong W, Qin C, Giorgi EE, Chen Z, Townsley S, Hu SL, Yu X, Gao F, Development of broad neutralization activity in simian/human immunodeficiency virus-infected rhesus macaques after long-term infection. AIDS. 2018 Mar 13;32(5):555-563.
114. Cheung KW, Wu T, Ho SF, Wong YC, Liu L, Wang H, Chen Z. α4β7 CD4 effector/effector memory T cells differentiate into productively and latently infected central memory T cells by transforming growth factor β1 during HIV-1 infection. Journal of Virology 2018 Mar 28;92(8). pii: e01510-17.
115. Chen M, Jia MH, Ma YL, Luo HB, Chen HC, Yang CJ, Dai J, Yang L, Dong LJ, Lu R, Song LJ, Han Y, Lu JY, Cheung AKL, Chen Z, Lu L. The changing HIV-1 genetic characteristics and transmitted drug resistance among recently infected population in Yunnan, China. Epidemiology & Infection. 2018 Apr;146(6):775-781.
116. Chen ZW, Liu L, Chen G, Cheung KW, Du Y, Yao X, Lu Y, Chen L, Lin X, Chen Z*. Surging HIV-1 CRF07_BC epidemic among recently infected men who have sex with men in Fujian, China. Journal of Medical Virology. 2018 Jul;90(7):1210-1221.
117. Tan Z, Liu L, Chiu MS, Cheung KW, Yan CW, Yu Z, Lee BK, Liu W, Man K, Chen Z*.Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression. Oncoimmunology. 2018 Oct 16;8(1):e1518672.

118. Ling L, Tang X, Huang X, Li J, Wang H, Chen Z*. AAV-Vectored Fms-Related Tyrosine Kinase 3 Ligand Inhibits CD34+ Progenitor Cell Engraftment in Humanized Mice. Journal of Neuroimmune Pharmacology. 2018 Dec;13(4):541-550.
119. Chen Z. Monkey Models and HIV Vaccine Research. Adv Exp Med Biol. 2018;1075:97-124. doi: 10.1007/978-981-13-0484-2_5.PMID: 30030791
120. Tang J, Cai Y, Liang J, Tan Z, Tang X, Zhang C, Cheng L, Zhou J, Wang H, Yam WC, Chen X, Wang H, Chen Z*. In vivo electroporation of a codon-optimized BERopt DNA vaccine protects mice from pathogenic Mycobacterium tuberculosis aerosol challenge. Tuberculosis (Edinb). 2018 Dec;113:65-75.
121. Cui H, Geng W, Sun H, Han X, An M, Jiang Y, Zhang Z, Chen Z, Xu J, Hu Q, Zhao B, Zhou B, Shang H. Rapid CD4+ T-cell decline is associated with coreceptor switch among MSM primarily infected with HIV-1 CRF01_AE in Northeast China. AIDS. 2019 Jan 27;33(1):13-22. doi: 10.1097/QAD.0000000000001981.PMID: 30102662
122. Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok HY, Tang HY, Nishiura K, Peng J, Tan Z, Wu T, Cheung KW, Chan KH, Alvarez X, Qin C, Lackner A, Perlman S, Yuen KY, Chen Z*. Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. Journal of Clinical Investigation Insight. 2019 Feb 21;4(4). pii: 123158.
123. Ling L, Wu T, To KKW, Cheung KW, Lui KO, Niu M, Lam KS, Wang CC, Li J, Wang H, Yuen KY, Chen Z*. Vedolizumab-mediated integrin α4β7 blockade does not control HIV-1SF162 rebound after cART interruption in humanized mice. AIDS. 2019 Jan 14.
124. Cheng L, Tang X, Xu L, Zhang L, Shi H, Peng Q, Zhao F, Zhou Y, He Y, Wang H, Zhou B, Gao Z, Chen Z*. Interferon-γ upregulates Δ42PD1 expression on human monocytes via the PI3K/AKT pathway. Immunobiology. 2019 May;224(3):388-396.
125. Cheung AKL, Huang Y, Chen M and Chen Z. Transfer of HIV-1 from HIV-1 latently infected CD34+ haematopoietic progenitors to CD4+ T cells. Hong Kong Med J. PMID: 31761770.
126. Liu M, Zhou J, Liu X, Feng Y, Yang W, Wu F, Cheung OK, Sun H, Zeng X, Tang W, Mok MT, Wong J, Yeung PC, Lai PBS, Chen Z, Jin H, Chen J, Chan SL, To KF, Sung JJ, Chen M, Cheng AS. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy   in   hepatocellular carcinoma.          2019 May 10. pii: gutjnl-2018-317257. doi: 10.1136/gutjnl-2018-317257
127. Wang P, Zheng M, Lau SY, Chen P, Mok BW, Liu S, Liu H, Huang X, Cremin CJ, Song W, Chen Y, Wong YC, Huang H, To KK, Chen Z, Xia N, Yuen KY, Chen H. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines. mBio. 2019 Sep 17;10(5):e02180-19
128. Tang X, Zhang S, Peng Q, Ling L, Shi H, Liu Y, Cheng L, Xu L, Cheng L, Chakrabarti LA, Chen Z, Wang H, Zhang Z. Sustained IFN-I stimulation impairs MAIT cell responses to bacteria by inducing IL-10 during chronic HIV-1 infection. Science Advances. 2020 Feb 19;6(8):eaaz0374. doi: 10.1126/sciadv.aaz0374. eCollection 2020 Feb.PMID: 32128419.
129. Tan Z, Chiu MS, Yan CW, Wong YC, Huang H, Man K, Chen Z*. Anti-mesothelioma Immunotherapy by CTLA-4 Blockade Depends on Active PD1-Based TWIST1 Vaccination. Molecular Therapy Oncolytics. 2020;16:302-317.
130. Chan JF, Zhang AJ, Yuan S, Poon VK, Chan CC, Lee AC, Chan WM, Fan Z, Tsoi HW, Wen L, Liang R, Cao J, Chen Y, Tang K, Luo C, Cai JP, Kok KH, Chu H, Chan KH, Sridhar S, Chen Z, Chen H, To KK, Yuen KY. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clinical Infectious Diseases. 2020 Mar 26:ciaa325.
131. To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, Yip CC, Cai JP, Chan JM, Chik TS, Lau DP, Choi CY, Chen LL, Chan WM, Chan KH, Ip JD, Ng AC, Poon RW, Luo CT, Cheng VC, Chan JF, Hung IF, Chen Z, Chen H, Yuen KY. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infectious Diseases. 2020 May;20(5):565-574. doi: 10.1016/S1473-3099(20)30196-1.
132. Lau SY, Wang P, Mok BW, Zhang AJ, Chu H, Lee AC, Deng S, Chen P, Chan KH, Song W, Chen Z, To KK, Chan JF, Yuen KY, Chen H. Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction. Emerging Microbes & Infections. 2020 Apr;9(1):837-842. doi: 10.1080/22221751.2020.1756700.
133. Wong YC, Lau SY, Wang To KK, Mok BWY, Li X, Wang P, Deng S, Woo KF, Du Z, Li C, Zhou J, Woo Chan JF, Yuen KY, Chen H, Chen Z*. Natural transmission of bat-like SARS-CoV-2PRRA variants in COVID-19 patients. Clin Infect Dis. 2020 Jul 10:ciaa953. doi: 10.1093/cid/ciaa953.
134. Liu L, To KK, Chan KH, Wong YC, Zhou R, Kwan KY, Fong CH, Chen LL, Choi CY, Lu L, Tsang OT, Leung WS, To WK, Hung IF, Yuen KY, Chen Z*. High neutralizing antibody titer in intensive care unit patients with COVID-19. Emerging Microbes & Infections. 2020 Jul;9(1):1664-1670. doi: 10.1080/22221751.2020.1791738.
135. Zhou R, To KK, Wong YC, Liu L, Zhou B, Li X, Huang H, Mo Y, Luk TY, Lau TT, Yeung P, Chan WM, Wu AK, Lung KC, Tsang OT, Leung WS, Hung IF, Yuen KY, Chen Z*. Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses. Immunity. 2020 Oct 13;53(4):864-877.e5. doi: 10.1016/j.immuni.2020.07.026
136. To KK, Hung IF, Chan KH, Yuan S, To WK, Tsang DN, Cheng VC, Chen Z, Kok KH, Yuen KY. Serum antibody profile of a patient with COVID-19 reinfection. Clinical Infectious Diseases. 2020 Sep 23:ciaa1368.
137. Zeng X, Tsui JC, Shi M, Peng J, Cao CY, Kan LL, Lau CP, Liang Y, Wang L, Liu L, Chen Z, Tsui SK. Genome-Wide Characterization of Host Transcriptional and Epigenetic Alterations During HIV Infection of T Lymphocytes. Front Immunol. 2020 Sep 10;11:2131. doi: 10.3389/fimmu.2020.02131. eCollection 2020.PMID: 33013899.
138. Yuan S, Chu H, Huang J, Zhao X, Ye ZW, Lai PM, Wen L, Cai JP, Mo Y, Cao J, Liang R, Poon VK, Sze KH, Zhou J, To KK, Chen Z, Chen H, Jin DY, Chan JF, Yuen KY. Viruses harness YxxØ motif to interact with host AP2M1 for replication: A vulnerable broad-spectrum antiviral target. Science Advances. 2020 Aug 28;6(35):eaba7910
139. Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L, Ho DD. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020 Aug;584(7821):450-456.
140. Liu L, Lin Q, Peng J, Fang J, Tan Z, Tang H, Kwan K, Nishiura K, Liang J, Kwok H, Du Z, Sun J, Liu K, Yuen KY, Wang H, Chen Z*. Persistent lentivirus infection induces early myeloid suppressor cells expansion to subvert protective memory CD8 T cell response. EBioMedicine. 2020 Sep 23; 60:103008.
141. Mo Y, Cheung ALK, Liu Y, Liu L, Chen Z*. 2020. D42PD1-TLR4 Augments gd-T Cell Activation of the Transitional Memory Subset of CD4+ T Cells. iScience. 2020 Oct 23; 23(10): 101620.
142. Chen Z. Editorial: The battle for survival between severe acute respiratory syndrome coronavirus 2 and human beings. Current Opinion HIV AIDS. 2020 Nov;15(6):325-327.
143. Tan Z, Chiu MS, Yan CW, Man K, Chen Z*. Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment. Molecular Therapy Oncolytics. 2021 Jan 21;20:373-386. doi: 10.1016/j.omto.2021.01.010.
144. Zhou D, Chan JF, Zhou B, Zhou R, Li S, Shan S, Liu L, Zhang AJ, Chen SJ, Chan CC, Xu H, Poon VK, Yuan S, Li C, Chik KK, Chan CC, Cao J, Chan CY, Kwan KY, Du Z, Lau TT, Zhang Q, Zhou J, To KK, Zhang L, Ho DD, Yuen KY, Chen Z*. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. Cell Host Microbe. 2021 Feb 25:S1931-3128(21)00098-6. doi: 10.1016/j.chom.2021.02.019.
145. Yang W, Feng Y, Zhou J, Cheung OK, Cao J, Wang J, Tang W, Tu Y, Xu L, Wu F, Tan Z, Sun H, Tian Y, Wong J, Lai PB, Chan SL, Chan AW, Tan PB, Chen Z, Sung JJ, Yip KY, To KF, Cheng AS. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Science Translational Medicine. 2021 Apr 7;13(588):eaaz6804. doi: 10.1126/scitranslmed.aaz6804. PMID: 33827976.
146. Wong YC, Liu W, Yim LY, Li X, Wang H, Yue M, Niu M, Cheng L, Ling L, Du Y, Chen SMY, Cheung KW, Wang H, Tang X, Tang J, Zhang H, Song Y, Chakrabarti LA, Chen Z*. Sustained viremia suppression by SHIVSF162P3CN-recalled effector-memory CD8+ T cells after PD1-based vaccination. PLoS Pathogens. 2021 Jun 14;17(6):e1009647.
147. Mo Y, Cheung AKL, Liu Y, Liu L, Chen Z*. Imaging and analysis on the interaction between human antigen-pulsed Vδ2 T cells and antigen-specific CD4 T cells. STAR Protocols. 2021 Apr 14;2(2):100453.
148. Yeung ML, Teng JLL, Jia L, Zhang C, Huang C, Cai JP, Zhou R, Chan KH, Zhao H, Zhu L, Siu KL, Fung SY, Yung S, Chan TM, To KK, Chan JF, Cai Z, Lau SKP, Chen Z, Jin DY, Woo PCY, Yuen KY. Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. Cell. 2021 Apr 15;184(8):2212-2228.e12.
149. Gong L, Kwong DL, Dai W, Wu P, Li S, Yan Q, Zhang Y, Zhang B, Fang X, Liu L, Luo M, Liu B, Chow LK, Chen Q, Huang J, Lee VH, Lam KO, Lo AW, Chen Z, Wang Y, Lee AW, Guan XY. Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma. Nature Communications. 2021 Mar 9;12(1):1540.
150. Li M, Guo J, Lu S, Zhou R, Shi H, Shi X, Cheng L, Liang Q, Liu H, Wang P, Wang N, Wang Y, Fu L, Xing M, Wang R, Ju B, Liu L, Lau SY, Jia W, Tong X, Yuan L, Guo Y, Qi H, Zhang Q, Huang Z, Chen H, Zhang Z, Chen Z, Peng X, Zhou D, Zhang L. Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection.  Front  Jun 28;12:697074. doi:      10.3389/fimmu.2021.697074. eCollection 2021.PMID: 34262569.
151. Wong YC, Lau SY, Wang To KK, Mok BWY, Li X, Wang P, Deng S, Woo KF, Du Z, Li C, Zhou J, Chan JFW, Yuen KY, Chen H, Chen Z*. Natural Transmission of Bat-like Severe Acute Respiratory Syndrome Coronavirus 2 Without Proline-Arginine-Arginine-Alanine Variants in Coronavirus Disease 2019 Patients. Clinical Infectious Diseases. 2021 Jul 15;73(2):e437-e444.
152. Zhang Q, Ju B, Ge J, Chan JF, Cheng L, Wang R, Huang W, Fang M, Chen P, Zhou B, Song S, Shan S, Yan B, Zhang S, Ge X, Yu J, Zhao J, Wang H, Liu L, Lv Q, Fu L, Shi X, Yuen KY, Liu L, Wang Y, Chen Z*, Zhang L, Wang X, Zhang Z. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. Nature Communications. 2021 Jul 9;12(1):4210. doi: 10.1038/s41467-021-24514-w. PMID: 34244522; PMCID: PMC8270942.
153. Niu M, Wong YC, Wang H, Li X, Chan CY, Zhang Q, Ling L, Cheng L, Wang R, Du Y, Yim LY, Jin X, Zhang H, Zhang L, Chen Z*. Tandem bispecific antibody prevents pathogenic SHIVSF162P3CN infection and disease progression. Cell Reports. 2021 Aug 24;36(8):109611.
154. Zhang Z, Guo L, Huang L, Zhang C, Luo R, Zeng L, Liang H, Li Q, Lu X, Wang X, Ma CY, Shao J, Luo W, Li L, Liu L, Li Z, Zhou X, Zhang X, Liu J, Yang J, Kwan KY, Liu W, Xu Y, Jiang H, Liu H, Du H, Wu Y, Yu G, Chen J, Wu J, Zhang J, Liao C, Chen HJ,  Chen  Z,  Tse  HF,  Xia  H,  Lian     Distinct   Disease   Severity   Between Children and Older Adults With Coronavirus Disease 2019 (COVID-19): Impacts of ACE2 Expression, Distribution, and Lung Progenitor Cells. Clin Infect Dis. 2021 Dec 6;73(11):e4154-e4165. doi: 10.1093/cid/ciaa1911.PMID: 33388749
155. Zhou D, Zhou R, Chen Z*. Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy. Immunotherapy Advances, Volume 2, Issue 1, 2022, ltab027, https://doi.org/10.1093/immadv/ltab027.
156. Wang P, Casner RG, Nair MS, Yu J, Guo Y, Wang M, Chan JF, Cerutti G, Iketani S, Liu L, Sheng Z, Chen Z, Yuen KY, Kwong PD, Huang Y, Shapiro L, Ho DD. A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. Emerging Microbes & Infections. 2022 Dec;11(1):147-157. doi: 10.1080/22221751.2021.2011623. PMID: 34836485; PMCID: PMC8725896.
157. Chu H, Hu B, Huang X, Chai Y, Zhou D, Wang Y, Shuai H, Yang D, Hou Y, Zhang X, Yuen TT, Cai JP, Zhang AJ, Zhou J, Yuan S, To KK, Chan IH, Sit KY, Foo DC, Wong IY, Ng AT, Cheung TT, Law SY, Au WK, Brindley MA, Chen Z, Kok KH, Chan JF, Yuen KY. Host and viral determinants for efficient SARS-CoV-2 infection of the human lung. Nature Communications. 2021 Jan 8;12(1):134.
158. Pang L, Ng KT, Liu J, Yeung WO, Zhu J, Chiu TS, Liu H, Chen Z, Lo CM, Man K. Plasmacytoid dendritic cells recruited by HIF-1α/eADO/ADORA1 signaling induce immunosuppression in hepatocellular carcinoma. Cancer Research. 2021 Dec 1;522:80-92.
159. Zhang BZ, Wang X, Yuan S, Li W, Dou Y, Poon VK, Chan CC, Cai JP, Chik KK, Tang K, Chan CC, Hu YF, Hu JC, Badea SR, Gong HR, Lin X, Chu H, Li X, To KK, Liu L, Chen Z, Hung IF, Yuen KY, Chan JF, Huang JD. A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters. Emerg Microbes Infect. 2021 Dec;10(1):874-884. doi: 10.1080/22221751.2021.1921621. PMID: 33890550
160. Mo Y, To KK, Zhou R, Liu L, Cao T, Huang H, Du Z, Lim CYH, Yim LY, Luk TY, Chan JM, Chik TS, Lau DP, Tsang OT, Tam AR, Hung IF, Yuen KY, Chen Z*. Mitochondrial Dysfunction Associates With Acute T Lymphocytopenia and Impaired Functionality in COVID-19 Patients. Frontiers in Immunology. 2022 Jan 14;12:799896. doi: 10.3389/fimmu.2021.799896.
161. Zhou R, Wang P, Wong YC, Xu H, Lau SY, Liu L, Mok BW, Peng Q, Liu N, Woo KF, Deng S, Tam RC, Huang H, Zhang AJ, Zhou D, Zhou B, Chan CY, Du Z, Yang D, Au KK, Yuen KY, Chen H, Chen Z*. Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. EBioMedicine. 2022 Jan;75:103762.
162. Zhou R, To KK, Peng Q, Chan MC, Huang H, Yang D, Lam HS, Chuang WM, Cai J, Liu N, Au KK, Tsang TY, Yuen KY, Chen Z*. Vaccine-breakthrough infection by the SARS-CoV-2 Omicron variant elicits broadly cross-reactive immune responses. Clinical and Translational Medicine. 2022 Jan 26;12;1;e720. Doi: 10.1002/ctm2.720
163. Peng Q, Zhou R, Wang Y, Zhao M, Liu N, Li S, Huang H, Yang D, Au KK, Wang H, Man K, Yuen KY, Chen Z*. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine. 2022 Mar 3;77:103904. doi: 10.1016/j.ebiom.2022.103904.
164. Chen SMY, Wong YC, Yim LY, Zhang H, Wang H, Lui GCY, Li X, Tang X, Cheng L, Du Y, Peng Q, Wang J, Kwok HY, Huang H, Lau TT, Chan DPC, Wong BCK, Liu L, Chakrabarti LA, Lee SS, Chen Z*. Enhanced Cross-Reactive and Polyfunctional Effector-Memory T Cell Responses by ICVAX-a Human PD1-Based Bivalent HIV-1 Gag-p41 Mosaic DNA Vaccine. Journal of Virology. 2022 Mar 17:e0216121. doi: 10.1128/jvi.02161-21. Epub ahead of print. PMID: 35297660.
165. Lian Q, Zhang K, Zhang Z, Duan F, Guo L, Luo W, Mok BW, Thakur A, Ke X, Motallebnejad P, Nicolaescu V, Chen J, Ma CY, Zhou X, Han S, Han T, Zhang W, Tan AY, Zhang T, Wang X, Xu D, Xiang J, Xu A, Liao C, Huang FP, Chen YW, Na J, Randall G, Tse HF, Chen Z, Chen Y, Chen HJ. Differential effects of macrophage subtypes on SARS-CoV-2 infection in a human pluripotent stem cell-derived model. Nature Communications. 2022 Apr 19;13(1):2028.
166. Liu L, Iketani S, Guo Y, Reddem ER, Casner RG, Nair MS, Yu J, Chan JF, Wang M, Cerutti G, Li Z, Morano NC, Castagna CD, Corredor L, Chu H, Yuan S, Poon VK, Chan CC, Chen Z, Luo Y, Cunningham M, Chavez A, Yin MT, Perlin DS, Tsuji M, Yuen KY, Kwong PD, Sheng Z, Huang Y, Shapiro L, Ho DD. An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Science Translational Medicine. 2022 May 25;14(646):eabn6859.
167. Ye ZW, Ong CP, Tang K, Fan Y, Luo C, Zhou R, Luo P, Cheng Y, Gray VS, Wang P, Chu H, Chan JF, To KK, Chen H, Chen Z, Yuen KY, Ling GS, Yuan S, Jin DY. Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals. Cellular & Molecular Immunology. 2022 May;19(5):588-601.
168. Chiu MC, Li C, Liu X, Yu Y, Huang J, Wan Z, Xiao D, Chu H, Cai JP, Zhou B, Sit KY, Au WK, Wong KK, Li G, Chan JF, To KK, Chen Z, Jiang S, Clevers H, Yuen KY, Zhou J. A bipotential organoid model of respiratory epithelium recapitulates high infectivity of SARS-CoV-2 Omicron variant. Cell Discovery. 2022 Jun 17;8(1):57.
169. Wang X, Chen X, Tan J, Yue S, Zhou R, Xu Y, Lin Y, Yang Y, Zhou Y, Deng K, Chen Z*, Ye L, Zhu Y. 35B5 antibody potently neutralizes SARS-CoV-2 Omicron by disrupting the N-glycan switch via a conserved spike epitope. Cell Host Microbe. 2022 Jun 8;30(6):887-895.e4.
170. Zhou B, Zhou R, Tang B, Chan JF, Luo M, Peng Q, Yuan S, Liu H, Mok BW, Chen B, Wang P, Poon VK, Chu H, Chan CC, Tsang JO, Chan CC, Au KK, Man HO, Lu L, To KK, Chen H, Yuen KY, Dang S, Chen Z*. A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge. Nature Communications. 2022 Jun 23;13(1):3589. doi: 10.1038/s41467-022-31259-7. PMID: 35739114; PMCID: PMC9223271.
171. Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, Wang M, Yu J, Bowen AD, Chang JY, Shah JG, Nguyen N, Chen Z, Meyers K, Yin MT, Sobieszczyk ME, Sheng Z, Huang Y, Liu L, Ho DD. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5. Nature. 2022 Jul 5. doi: 10.1038/s41586-022-05053-w. Epub ahead of print. PMID: 35790190.
172. Ye ZW, Fan Y, Tang K, Ong CP, Luo C, Chung HL, Leong TL, Liang R, Lui WY, Zhou R, Cheng Y, Lu L, Cheung PH, Chan JF, Chen Z, Yuen KY, Yuan S, To KK, Jin DY. Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines. Int J Biol Sci. 2022 Jul 13;18(12):4781-4791. doi: 10.7150/ijbs.72109. eCollection 2022.PMID: 35874942.
173. Liu Q, Kwan KY, Cao T, Yan B, Ganesan K, Jia L, Zhang F, Lim C, Wu Y, Feng Y, Chen Z*, Liu L, Chen J. Broad-spectrum antiviral activity of Spatholobus suberectus Dunn against SARS-CoV-2, SARS-CoV-1, H5N1, and other enveloped viruses. Phytotherapy Research. 2022 Aug;36(8):3232-3247.
174. Peng Q, Zhou R, Liu N, Wang H, Xu H, Zhao M, Yang D, Au KK, Huang HD, Liu L and Chen Z*. Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2. Cellular & Molecular Immunology. 2022 Nov;19(11):1302-1310. doi: 10.1038/s41423-022-00924-8. Epub 2022 Oct 12.
175. Peng Q, Liu X, Tang X, Zhang Q, Zhao J, Zheng C, Zhao F, Zhou Y, Zhang L, Sun L, Zhang H, Jia X, Song Y, Cao T, Wang S, Rao M, Chen Z, Wang H, He Y. Low rate of pre-exposure prophylaxis and post-exposure prophylaxis uptake and high prevalence of transmitted drug resistance among newly diagnosed primary HIV infections in Shenzhen, China: a real-world retrospective study. Chinese Medical Journal (Engl). 2022 Nov 20;135(22):2730-2737.
176. Cao T, Liu L, To KK, Lim CY, Zhou R, Ming Y, Kwan KY, Yu S, Chan CY, Zhou B, Huang H, Mo Y, Du Z, Gong R, Yat LT, Hung IF, Tam AR, To WK, Leung WS, Chik TS, Tsang OT, Lin X, Song YQ, Yuen KY, Chen Z*. Mitochondrial regulation of acute extrafollicular B-cell responses to COVID-19 severity. Clinical and Translational Medicine. 2022 Sep;12(9):e1025.
177. Pang L, Yeung OWH, Ng KTP, Liu H, Zhu J, Liu J, Yang X, Ding T, Qiu W, Wang Y, Chiu TLS, Chen Z, Lo CM, Man K. Postoperative Plasmacytoid Dendritic Cells Secrete IFNα to Promote Recruitment of Myeloid-Derived Suppressor Cells and Drive Hepatocellular Carcinoma Recurrence. Cancer Research. 2022 Nov 15;82(22):4206-4218.
178. Tan Z, Chiu MS, Yang X, Yue M, Cheung TT, Zhou D, Wang Y, Chan AW, Yan CW, Kwan KY, Wong YC, Li X, Zhou J, To KF, Zhu J, Lo CM, Cheng AS, Chan SL, Liu L, Song YQ, Man K, Chen Z*. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients. Gut. 2022 Nov 30:gutjnl-2022-327133.
179. Zhao F, Fung TY, Chen Z*, Wang H*, Cheung AKL*. Association of human cytomegalovirus in urine with end-organ diseases in stage 2/3 HIV-1-infected individuals. Journal of Clinical Virology. 2023 Jan;158:105351.
180. Zhou R, Liu N, Li X, Peng Q, Yiu CK, Huang H, Yang D, Du Z, Kwok HY, Au KK, Cai JP, Fan-Ngai Hung I, Kai-Wang To  K,  Xu  X,  Yuen  KY,  Chen  Z*.  Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong. The Lancet Regional Health – Western Pacific. 2023 Mar;32:100660.
181. Luo M, Zhou B, Reddem ER, Tang B, Chen B, Zhou R, Liu H, Liu L, Katsamba PS, Au KK, Man HO, To KK, Yuen KY, Shapiro L, Dang S, Ho DD, Chen Z*. Structural insights into broadly neutralizing antibodies elicited by hybrid immunity against SARS-CoV-2. Emerging Microbes & Infections. 2023 Dec;12(1):2146538.
182. Zhang R, Chan KH, Wang P, Zhou R, Yau HK, Wong CK, Au MW, Tam AR, Ng CT, Lou MK, Liu N, Huang H, Deng S, Tam RC, Liu Y, Long T, Tsoi HW, Ng MKW, Cai JP, To KK, Yuen MF, Chen Z, Chen H, Yuen KY, Hung IF. A Phase 1, Randomized, Double-Blinded, Placebo-Controlled and Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the Intranasal DelNS1-nCoV-RBD LAIV for COVID-19 in Healthy Adults. Vaccines (Basel). 2023 Mar 24;11(4):723. doi: 10.3390/vaccines11040723. PMID: 37112634; PMCID: PMC10143096.
183. Cai JP, Luo C, Wang K, Cao H, Chen LL, Zhang X, Han Y, Yin F, Zhang AJ, Chu H, Yuan S, Kok KH, To KK, Chen H, Chen Z, Jin DY, Yuen KY, Chan JF. Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice. Viruses. 2023 Mar 6;15(3):687. doi: 10.3390/v15030687. PMID: 36992395; PMCID: PMC10052291.
184. Deng S, Liu Y, Tam RC, Chen P, Zhang AJ, Mok BW, Long T, Kukic A, Zhou R, Xu H, Song W, Chan JF, To KK, Chen Z, Yuen KY, Wang P, Chen H. An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters. Nat Commun. 2023 Apr 12;14(1):2081. doi: 10.1038/s41467-023-37697-1. PMID: 37045873; PMCID: PMC10092940.
185. Zhou J, Jiang S, Zhou T, Chen Z, Jin X, Zhang W, Rerks-Ngarm S, Kramvis A, Deng K, Zhang L. Editorial: AIDS 40th Year. Front Microbiol. 2023 Mar 31;14:1184684. doi: 10.3389/fmicb.2023.1184684. PMID: 37065161; PMCID: PMC10102659.
186. Yim LY, Lam KS, Luk TY, Mo Y, Lu X, Wang J, Cheung KW, Lui GCY, Chan DPC, Wong BCK, Lau TT, Ngan CB, Zhou D, Wong YC, Tan Z, Liu L, Wu H, Zhang T, Lee SS, Chen Z*. Transforming Growth Factor β Signaling Promotes HIV-1 Infection in Activated and Resting Memory CD4+ T Cells. J Virol. 2023 May 31;97(5):e0027023. doi: 10.1128/jvi.00270-23. Epub 2023 Apr 12. PMID: 37042759; PMCID: PMC10231204.
187. Zhai J, Chen H, Wong CC, Peng Y, Gou H, Zhang J, Pan Y, Chen D, Lin Y, Wang S, Kang W, To KF, Chen Z, Nie Y, He HH, Sung JJ, Yu J. ALKBH5 Drives Immune Suppression Via Targeting AXIN2 to Promote Colorectal Cancer and Is a Target for Boosting Gastroenterology.       2023    Aug;165(2):445-462.  doi: 10.1053/j.gastro.2023.04.032. Epub 2023 May 9. PMID: 37169182.
188. Chen S, Tan Z, Liao P, Li Y, Qu Y, Zhang Q, Yang M, Chan KWY, Zhang L, Man K, Chen Z, Sun D. Biodegradable Microrobots for DNA Vaccine Delivery. Adv Healthc Mater. 2023 May 8:e2202921. doi: 10.1002/adhm.202202921. Epub ahead of print. PMID: 37156574.
189. Zhou B, Zhou R, Chan JF, Zeng J, Zhang Q, Yuan S, Liu L, Robinot R, Shan S, Liu N, Ge J, Kwong HY, Zhou D, Xu H, Chan CC, Poon VK, Chu H, Yue M, Kwan KY, Chan CY, Chan CC, Chik KK, Du Z, Au KK, Huang H, Man HO, Cao J, Li C, Wang Z, Zhou J, Song Y, Yeung ML, To KK, Ho DD, Chakrabarti LA, Wang X, Zhang L, Yuen KY, Chen Z*. SARS-CoV-2 hijacks neutralizing dimeric IgA for nasal infection and injury in Syrian hamsters. Emerg Microbes Infect. 2023 Aug 5:2245921. doi: 10.1080/22221751.2023.2245921. Epub ahead of print. PMID: 37542391
190. He X, Wong YC, Zhong M, Mo Y, Li B, Yim LY, Li X, Liu W, Du Y, Wang H, Zhang H, Chen Z*. A follow-up study: 6-year cART-free virologic control of rhesus macaques after PD-1-based DNA vaccination against pathogenic SHIVSF162P3CN challenge. Microbiology Spectrum. 2023 Dec 12;11(6):e0335023. doi: 10.1128/spectrum.03350-23. Epub 2023 Nov 3. PMID: 37921496; PMCID: PMC10715146.
191. Tan Z, Chiu MS, Yue M, Kwok HY, Tse MH, Wen Y, Chen B, Yang D, Zhou D, Song YQ, Man K, Chen Z*. Enhancing the efficacy of vaccinia-based oncolytic virotherapy by inhibiting CXCR2-mediated MDSC trafficking. Journal of Leukocyte Biology. 2023 Dec 8:qiad150. doi: 10.1093/jleuko/qiad150.
192. H Xu, M Yue, R Zhou, P Wang, MYC Wong, J Wang, H Huang, B Chen, Y Mo, R CY Tam, B Zhou, Z Du, H Huang, L Liu, Z Tan, KY Yuen, Y Song, H Chen, ZW Chen*. Lung resident memory CD8+ T cells derived from Central memory T cells prevent tumor lung metastasis. Cancer Review. (Under Review)

1. Chen Z. SIV-specific DNA in Museum Specimens from Non-human Primates. New Mexico State University,
2. Chen Z. Evolution and characterization of primate lentiviruses (SIVsm and HIV-2) in West Ph.D. Dissertation. New York University Publications, 1996.
3. AIDS – Laboratory techniques and quality control. Chapter 3: Specific immune response against HIV-1 2009, Science Press, Beijing, People’s Republic of China.
4. HIV Immunology. Chapter 6: HIV-1 Mucosal Immunity, Science Press, Beijing, People’s Republic of China, in
5. HIV Manual 2013, Chapter One, Centre for Health Protection, Department of Health, Hong Kong Special Administrative Region
6. HIV Vaccines and Cure: The Path Towards Finding an Effective Cure and Chapter 5. Springer Nature Singapore Pte Ltd. 2018.
7. HIV Manual 2019, Chapter One, Hong Kong, Publisher:

1. 12th Annual Symposium on Non-human Primate Models for AIDS, Oct 12-15, 1994; Boston, Massachusetts,
2. 13th Annual Symposium on Non-human Primate Models for AIDS, 5-8, 1995; Monterey, California, USA.
3. 14th Annual Symposium on Non-human Primate Models for AIDS, Oct.23-26, 1996; Portland, Oregon, USA (Late breaker, Identification of Rhesus CCR5 as entry co-receptor of diverse SIV).
4. 4th Conference on Retroviruses and Opportunistic Infections, Jan. 22-26, 1997; Washington C., USA (Genetically Divergent Simian Immunodeficiency Viruses Use CCR5 but not CXCR4 as a Coreceptor for Entry)
5. Symposium on HIV/AIDS Prevention and Care, May 20, 1997; Beijing,
6. 15th Annual Symposium on Non-human Primate Models for AIDS, Sept. 3-6, 1997; Seattle, Washington,
7. 16th Annual Symposium on Non-human Primate Models for AIDS, Oct. 3-6, 1998; Atlanta,
8. 6th Conference on Retroviruses and Opportunistic Infections, Jan. 22-26, 1999; Chicago, USA (Natural Infection of a Red-Capped Mangabey with a Homozygous CCR5 Defect (d24) by a CCR2b-Tropic Simian Immunodeficiency Virus).
9. 1st AIDS Symposium at Chung Shan Medical & Dental College, Feb. 25-26, 1999; Taichung,
10. The Fifth International AIDS Conference at Taipei, 27-Mar. 1, 1999; Taipei, Taiwan.
11. The Sixth International AIDS Conference at Chung Shan Medical & Dental College, Feb. 25-26, 2000; Taichung,
12. The 2001 Workshop of Aaron Diamond AIDS Research Center, Emory Vaccine Center and UCLA AIDS Institute Collaborative Vaccine, June 26&27, 2001; Los Angeles, USA
13. 19th Annual Symposium on Non-human Primate Models for AIDS, 7-10, 2001; San Juan, Puerto Rico.
14. AIDS Vaccine Conference 2003, Sept. 18-23, Hilton New York, New York City, ,
15. International meeting on emerging infectious disease and AIDS at Wuhan University, 16-17, 2004; P.R. China.
16. Expert Group Meeting on HIV/AIDS in China, Aug. 26, 2005; Beijing, R. China, organized by CAMS/MOH.
17. AIDS Vaccine Conference 2006, Aug 28-Sept. 2, 2006; RAI, Amsterdam, the Netherlands.
18. 13th SNIP Annual Conference – Neuroimmune Circuits and Infectious Disease, April 10-14, 2007, Salt Lake City, Utah,
19. International Conference on Modern Mucosal Vaccine, Adjuvants and Microbicides, Oct. 22-24, 2008, Porto,
20. Scientific, regulatory and public health aspects of microbicide research and development, Nov 3-6, 2008, Nanjing, China. Organized by WHO and NJU. Chair of the plenary session 3.
21. Second Ditan International Conference on Infectious Diseases. Nov 14-17, 2008, Beijing, China. Chair of the session for HIV/AIDS.
22. 8th Asia-Pacific Congress of Medical Feb 25-28, 2009, Hong Kong, China.
23. 15th Society on NeuroImmune Pharmacology Conference. Apr 21-24, 2009. Wuhan, China.
24. Second Annual World Summit of Antivirals. Jul 18-20, 2009. Beijing, China.
25. Third Ditan International Conference on Infectious Diseases. Jul 30 – Aug 2, 2009. Beijing, China.
26. AIDS Vaccine 2009, Satellite meeting on replicating viral vaccine vectors; Oct 19-22, Paris, France.
27. Frontiers in Biomedical Research HKU 2009. Dec 4, 2009. Hong Kong, China.
28. 2010 Annual General Meeting and Scientific Meeting of Hong Kong Society for Immunology. Apr 17, 2010.   Hong Kong, China. Role: Keynote Speaker (“Control of a pathogenic SIVmac239 infection by a heterologous mucosal prime and intramuscular boost vaccination strategy”)
29. Symposium on HIV ART updates, organized by Shenzhen Third People’s Hospital, Shenzhen, China April 24, 2010, Role: Keynote Speaker
30. China AIDS Vaccine Initiative (CAVI) Executive Committee Meeting & The Second China AIDS Vaccine Forum. May 10-14, 2010. Shanghai, China. Role: Speaker
31. Fourth Ditan International Conference on Infectious Diseases. Jul 15 – 18, Beijing, China.
32. 1st World Congress of Virus and Infections 2010. July 31 – Aug 3, 2010. Busan, South Korea (SAB member and section Chairman).
33. The 4th International Symposium on Emerging Viral Diseases. Oct 24-27, 2010. Wuhan, China.
34. “Tsinghua-Yue-Yuen Symposium on Medical Sciences 2011”at Tsinghua University, April 12, 2011, titled of speech: “Novel mechanism of SARS-CoV transmission”
35. CAVI Meeting, talk titled: “A Novel Vaccine Design for Inducing Robust HIV-1 Specific Immunity”, September 17, 2011.
36. Phacilitate Vaccine Forum Singapore, Talk Titled: “Induction of robust HIV-1 specific T cell immunity”, September 19-21, 2011 (invited Speaker and Panelist)
37. “Forum of Frontier Virology”, Invited lecturer and oral presenter, Beijing, October 12, 2011. Chinese Academy of Sciences.
38. Heterologous immunization induces potent anti-SIV immunity with qualitative and quantitative improvements. Immunology 2011 98th Annunal Meeting 186:53.22 Tang  X & Chen Z. (2011).
39. 18th Society on NeuroImmune Pharmacology (SNIP) Conference in Honolulu, HI, invited to co-chair for the “Spice and Bath Salts – An Emerging Health Risk in the United States” Symposium (both Oral and Poster Presentation) Titled: “Infection of Chinese Macaques by a Neurotropic SIVmac251/CNS without and with Tetrahydrocannabinal (THC)” April 24-28, 2012.
40. 2012 National Institute on Drug Abuse (NIDA) International forum – New and Emerging Psychoactive Substances: Second Interdisciplinary Forum, Palm Springs, USA, Abstract titled: “Tetrahydrocannabinal (THC) Effect on SIVmac251 Infection in Chinese Macaques”, Invited Lecturer and featured guest, June 8-13, 2012.
41. College on Problems of Drug Dependence (CPDD) Workshop: Chinese and Global Health, Invited Speaker (Oral and Poster Presentation); June 12, 2012
42. AIDS Vaccine Conference 2012, Boston, USA, September 9-12, 2012 (Oral and Poster Presentation).
43. Frontiers in Biomedical Research HKU 2012. Dec 14, 2012.  Hong Kong, China.  Invited Speaker and Section Chair.
44. International conference on Global Health: Prevention and Treatment of Substance Use Disorders and HIV in Taipei, Taiwan, talk titled: “Potentiating HIV-Specific CTL via Dendritic Cells” Invited Speaker, April 17-19, 2013.
45. Invited speaker, Promoting global health—treatment and prevention of substance abuse and HIV in Asia, held in Taiwan in 2015.
46. Invited speaker, Promoting global health—treatment and prevention of substance abuse and HIV in Asia, held in UCLA, USA in 2016.
47. Invited speakers at The International Global Virus Network (GVN) Meeting hosted by The Peter Doherty Institute for Infection and  Immunity  in    September 25-27, 2017.
48. Invited speaker, “A novel tandem bispecific neutralizing antibody for HIV-1 functional cure”, Xiangshan Meeting, 27 April 2018, Beijing
49. Invited speaker, “Humanized NSG Mouse Models for HIV/AIDS”, Nanjing 26 September 2018.
50. Invited speaker, HIV Research for Prevention (HIVR4P) 2018, the only global scientific conference focused exclusively on the challenging and fast-growing field of biomedical HIV prevention research, Oct. 21-25, 2018 at Madrid Marriott Auditorium, Madrid, Spain.
51. Invited speaker, The 5th AIDS Forum of Beijing, Hong Kong, Macau and Taiwan, on “HIV Immunotherapy”, 12 April 2019, Taipei.

1. Institute of Microbiology, Chinese Academy of Sciences, China, 2000.
2. School of Life Science and Engineering, Tsinghua University, China, 2001.
3. The Chinese University of Hong Kong, Dept of Chemistry, China, 2001.
4. College of Life Sciences, Wuhan University, China, 2001.
5. College of Life Sciences, Wuhan University, China, 2002.
6. College of Life Sciences, Beijing University, China, 2002.
7. Section of Microbial Pathogenesis, Yale University School of Medicine, USA, 2003.
8. Center for Public Health Research, Nanjing University, China, 2004.
9. Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 2007.
10. Louisiana State University Health Sciences Center, USA, 2007.
11. Tulane Regional Primate Research Laboratory, USA, 2007.
12. Pearl River Delta AIDS Vaccine Forum, Guangzhou, Oct 12-13, 2007.
13. HIV/AIDS Research Conference, Oct 13-19, 2007, Beijing.
14. Forum on AIDS and Hepatitis vaccines; organized by the Chinese Academy of Sciences, Beijing, Nov 29, 2007.
15. International conference on AIDS vaccine preparedness; co-organized by International AIDS Vaccine Initiative and the Chinese Academy of Medical Sciences, Guangxi, Dec 3-5, 2007.
16. “HIV/AIDS: Unanswered Questions” at Queen Elizabeth Hospital, July 25, 2008, Hong Kong.
17. “中國科學院 2008 年傳染病學術交流會” organized by the Chinese Academy of Sciences, Guangzhou, Jan 3-5, 2008.
18. Global Health Lessons through the Lens of HIV/AIDS, Beijing, Nov 11, 2008. Co Organized by Ministry of Health of China and Harvard University.
19. CAMS-IAVI HIV/AIDS Vaccine Workshop; “為愛滋病疫苗創建最佳社會配套環境研 討 會 ” co-organized by International AIDS Vaccine Initiative and the Chinese Academy of Medical Sciences, Beijing, Nov 18-19, 2008.
20. Yunnan CDC 7th Anniversary Conference and Director Meeting, organized by Yunnan CDC, Kunming, Dec 16-19, 2008.
21. The first scientific forum on AIDS; “第一届愛滋病科學論壇”, organized by the Chinese CDC, Beijing, Dec 22, 2008.
22. Cross Strait Workshop on Emerging Infectious Diseases, Xiamen, Sept 17-20, 2009, China.
23. CAVI-IAVI 2009 AIDS Vaccine  Network Meeting,  Nov.  9-10, 2009, Beijing.      (CAVI: Chinese AIDS Vaccine Initiative; IAVI: International AIDS Vaccine Initiative).
24. 愛滋病專題學術研討會 organized by Institut Pasteur of Shanghai, Chinese Academy of Sciences, Mar 19, 2010, Shanghai.
25. Invited Speaker 深圳巿繼續教育學習班《2010 深圳巿愛滋病篩查實驗室品質考評工作培訓班》, organized by Shenzhen CDC, Shenzhen, China, May 27, 2010.
26. 深圳巿繼續教育學習班《愛滋病抗病毒治療的新進展》organized by Shenzhen Third People’s Hospital, April 24, 2010, Shenzhen, China.
27. Institut of Pasteur Shanghai, Chinese Academy of  Sciences, May 10, 2010. Shanghai, China.
28. “The fifth China Health communication Conference and Tsinghua public health science conference” at Tsinghua University in Beijing, Nov 4-5, 2010.
29. “Tsinghua-Yue-Yuen Symposium on Medical Sciences 2011” at Tsinghua University, April 12, 2011, titled of speech: “解密沙士(SARS)病毒传播的新机制”.
30. “Canossian Global Youth Conference” July 18, 2011, Hong Kong.
31. Invited Seminar at the Department of Biomedical Sciences, UNT Health Science Center, Fort Worth, Texas; Seminar titled: “Antigen targeting to DCs by soluble PD-1 amplifies HIV-1 Gag CD8+ T-cell immunity” June 13-16, 2012. USA.
32. NIDA Neuroscience Consortium Cutting-edge seminar series, symposium entitled “HIV/NeuroAIDS Treatment and Prevention beyong HAART – Thinking Outside the Box”. Talk titled: “Vaccine: A Possible Solution to Protect against HIV/NeuroAIDS”. (Invited Speaker/Expert), June 18, 2012. NIH, USA.
33. Invited lecture, Hong Kong AIDS Foundation for hundreds of local community people on our PD1-based vaccine in 2013.
34. Invited speaker, “艾滋病疫苗与免疫根治研究”, 廣州, 5 Janury 2015.
35. Invited speaker, “Biomedical Prevention and Possible Cure of HIV/AIDS”, Hospital Authority Convention, 19 May 2015, Hong Kong.
36. Invited speaker at The Aaron Diamond AIDS Research Center, The Rockefeller University, USA. July 2015.
37. Invited seminar speaker at the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, USA. July 2015.
38. A talk entitled “PD1-based vaccines for AIDS and cancer immunotherapy” at Institut Pasteur, Paris, France. October 2015.
39. Invited seminar speaker, “Immunology and Cancer Research”, 4 March 2016, CUHK.
40. Invited speaker, A potent bi-specific bnAb for HIV prevention and immunotherapy. Tianjin, 17 Nov 15 2016.
41. Invited seminar speaker, “Antibody Engineering for HIV Prevention and Immunotherapeutic Cure”, The 78th Academic Seminar on Biomedicine and Biotechnology. 1 December 2016, Chinese Academy of Science.
42. Invited lectures at world-leading research institutions and universities to exchange our findings on PD1-based vaccine including (1) US National Institute of Health for The Neuroscience Consortium Cutting Edge Symposium, (2) The Ragon Institute of MGH, MIT and Harvard, (3) The Aaron Diamond AIDS Research Center of Rockefeller University, and (4) Institut Pasteur in Paris.
43. Invited speaker, 中华医学会第七次全国艾滋病、病毒性丙型肝炎暨全国热带病学术会议 2015 年 9 月 18 日深圳.
44. Invited speaker, 粤港澳大湾区合作发展座谈会, 12 May 2018, HKU.
45. Invited speaker, 国家卫生健康委员会代表团座谈会 2018 年 5 月 8 日, 国家新发传染病重点实验室.
46. Invited speaker, “登峰计划” 高峰论坛之 —— 肿瘤多学科研究新策略 ,香港大学深圳医院，香港大学外科系 , 2018 年 12 月 14 日地点：香港大学深圳医院学术会议中心.
47. Invited speaker, Croucher Foundation Sponsored Conference 2018/2019, Gut Microbiome as a Biomarker and Therapy for Cancer Immunotherapy, 26 April 2019.
48. Invited speaker, HIV or not, does it make a difference under COVID-19? September 16, 2021, Cheung Kung Hai Conference Centre, William MW Mong Block, 21 Sassoon Road.
49. Invited speaker, The 40th Anniversary of HIV Discovery. November 30, 2021 Guangdong-HongKong Greater Bay Area AIDS Prevention and Control Seminar (Webinar)
50. Invited Speaker for Webinar: Advances in COVID Management Vaccines/ Treatment and Technologies. March 18, 2022 Organized by Society For Innovative Healthcare Hong Kong.
51. Invited Speaker for Webinar: 2022 愛滋病專防冶专家高層對話 August 21, 2022, Organized by 廣東省性病愛滋病防冶協會
52. Invited Speaker, Recent Advances in HIV Cure Research, 2nd Symposium on Combating Infectious Diseases, December 16, 2022, Lecture Theatre 2, G/F, William MW Mong Block, 21 Sassoon Road

Graduate research students supervised

(Please include only students in respect of whom you are the principal supervisor)

• Number of research students supervised

• For graduated research students